Search
# Popular search #
# Popular search #
Stock Code
603087.SHGan & Lee Pharmaceuticals Shines at CPHI Worldwide 2024 in Milan
Gan & Lee Pharmaceuticals’ Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies
[EASD 2024 Highlights] Once-weekly Insulin GZR4
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
Gan & Lee Pharmaceuticals to Present Positive Data from Two Clinical Studies of GZR4, a Once-weekly Insulin, at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
Gan & Lee’s Insulin Glargine U300 Clinical Research Findings Published in Frontiers in Endocrinology
To be a world-class pharmaceutical company with focus on global business development
Registered in 20 countries
Products launched in 18 countries
Clinical trials conducted in 12 countries
Registered in 20 countries
Products launched in 18 countries
Clinical trials conducted in 12 countries
This website uses cookies to give users like yourself the best possible content and experience. For more information about your choices regarding cookies, please review our Privacy Policy .
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.